NANJING, China, July 27, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2011 on Tuesday, August 9, 2011, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Tuesday, August 9 at 8 p.m. Beijing/Hong Kong time).
To access the conference call, please dial:United States toll-free:+1.866.510.0708International:
10.800.130.0399 / 10.800.120.2655 / 10.800.152.1490China Netcom:
10.800.852.1490 / 10.800.712.2655China 400 (for mobile users)
400.881.1630 / 400.881.1629Hong Kong:
+852.3002.1672Please ask to be connected to Q2 2011 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 72942369.
Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.
Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:+1.888.286.8010International:
+1.617.801.6888The passcode for replay participants is 99140552. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.
About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.
Investor and Media Contacts: Email: firstname.lastname@example.orgIn Nanjing:Yehong Zhang
Simcere Pharmaceutical GroupTel: 86-25-8556-6666 ext 8811In the United States:Cindy Zheng
Tel: 1-212-333-3810In Beijing:Yue Yu
Tel: 86-10-5960-8600In Hong Kong:Joseph Lo Chi-Lun
|SOURCE Simcere Pharmaceutical Group|
Copyright©2010 PR Newswire.
All rights reserved